| 1978N-0065 | Skin Bleaching Drug Products | |||||||||||||||||||||||
| FDA Comment Number : | EC130 | |||||||||||||||||||||||
| Submitter : | Dr. Jamison Strahan | Date & Time: | 12/08/2006 08:12:36 | |||||||||||||||||||||
| Organization : | Dr. Jamison Strahan | |||||||||||||||||||||||
| Category : | Health Professional | |||||||||||||||||||||||
| Issue Areas/Comments | ||||||||||||||||||||||||
| GENERAL | ||||||||||||||||||||||||
| GENERAL | ||||||||||||||||||||||||
| Food and Drug Administration
ATTN: Division of Dockets Management 5630 Fishers Lane, Room 1061, HFA-301 Rockville, MD 20852 docket number 1978N-0065, RIN 0910-AF53 I am writing request that hydroquinone NOT be removed by the FDA. Hydroquinone is one of the most effective molecules for the treatment of dark discoloration over the past 40-50 years and has been used in millions of people. It is used to treat the top concerns among our patients including melasma, photo-aging, post-inflammatory hyperpigmentation, medically and cosmetic disfiguring dyschromias. Since 1961, hydroquinone has demonstrated a safe and effect profile among clinicians prescribing or recommending hydroquinone products. In spite of humans exposure to natural sources of hydroquinone in wheat, pears, berries, coffee, tea, onions, rice and red wine, there is not an association with carcinogenicity. There have been no reported cases of related malignancies in more than 50 years of manufacture and use of HQ. | ||||||||||||||||||||||||